Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Net Income
(171,799)
(133,969)
(176,353)
(114,347)
Operating Activities, Cash Flows Provided By or Used In
Depreciation
47,187
56,744
47,264
45,295
Changes In Accounts Receivables
(16,367)
(26,650)
(8,756)
(4,227)
Changes In Assets and Liabilities
46,332
(30,340)
(23,084)
33,059
Changes In Inventories
(50,989)
(36,847)
(33,910)
1,423
Changes In Other Operating Activities
(76,053)
97,523
135,205
56,406
Total Cash Flow From Operating Activities
(221,689)
(73,539)
(59,634)
17,609
Investing Activities, Cash Flows Provided By or Used In
Capital Expenditures
(227,653)
(118,834)
(65,124)
(44,571)
Investments
(451,797)
247,889
(107,284)
(151,074)
Other Cash flows from Investing Activities
(500,148)
65,500
(126,375)
0
Total Cash Flows From Investing Activities
(1,179,598)
194,555
(298,783)
(195,645)
Financing Activities, Cash Flows Provided By or Used In
Dividends Paid
--
--
--
--
Sale/Purchase of Stock
888,257
117,464
0
235,499
Net Borrowings
--
0
712,630
(5,083)
Other Cash Flows from Financing Activities
39,656
68,225
34,041
81,875
Total Cash Flows From Financing Activities
927,913
185,689
746,671
312,291
Effect Of Exchange Rate Changes
(5,072)
(3,398)
(2,230)
--
Change In Cash and Cash Equivalents
(478,446)
306,705
388,254
134,255

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information